Browse studies

Find your next paid study

8 recruiting studies matching your filters

Phase I/II Trial of Systemic Targeted Radioligand Therapy (TRT) With Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR Positive (SSTR+) Gastrointestinal (GI) Neuroendocrine Tumors (NET) and Pheochromocytoma/Paragangliomas Previously Treated With Systemic Radioligand Therapy

Background: Gastrointestinal neuroendocrine tumors (GI NET) are a type of cancer that affects the stomach and intestines; pheochromocytoma/paragangliomas (PPG…

Somatostatin Receptor PositiveGastrointestinal Neuroendocrine TumorsPheochromocytoma+1 more

Estimated

~$150 – $2,700

Actual pay is set by the research site.

National Cancer Institute (NCI)NCT06427798

Phase 1

A Multicenter, Open-label, Interventional Phase I Trial to Determine the Dose and Evaluate the Pharmacokinetics (PK) and Safety of Lutetium Lu 177 Edotreotide Targeted Radiopharmaceutical Therapy (RPT) as Monotherapy or Following Standard of Care (SoC) for the Treatment of Somatostatin Receptor-positive Tumors in the Pediatric Population (KinLET).

The purpose of the study is to determine the appropriate pediatric dosage and evaluate the pharmacokinetics (PK) and safety of Lutetium Lu 177 Edotreotide Targ…

Somatostatin Receptor PositiveNETsLymphoma+5 more

Estimated

~$150 – $4,200

Actual pay is set by the research site.

ITM Solucin GmbHNCT06441331

Phase 4

The DEterminig Statin Intolerance for Rosuvastatin Trial

The DESIFOR pilot study was conducted to determine the feasibility of utilizing an n-of-1 trial to facilitate tolerance of unblinded rosuvastatin in patients w…

Statin TherapyStatin Adverse ReactionStatin

Estimated

~$25 – $1,000

Actual pay is set by the research site.

Minneapolis Heart Institute FoundationNCT06804980

Phase 2

A Phase 2, Double-Blind Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of Apitegromab in Subjects <2 Years Old With Spinal Muscular Atrophy (SMA)

This double-blind, Phase 2, multiple-dose study will be conducted to evaluate the PK/PD, efficacy, safety, and tolerability of apitegromab in subjects \<2 year…

Spinal Muscular AtrophySMASpinal Muscular Atrophy Type 2+3 more

Estimated

~$75 – $2,800

Actual pay is set by the research site.

Scholar Rock, Inc.NCT07047144

Phase 3

A Phase III Multi-center, Randomized, Open-label Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients Newly Diagnosed With Grade 1 and Grade 2 (Ki-67 <10%) Advanced GEP-NET With High Disease Burden (NETTER-3)

The purpose of the current study is to evaluate the efficacy and safety of \[177Lu\]Lu-DOTA-TATE plus octreotide long-acting release (LAR) versus octreotide LA…

Somatostatin Receptor Positive (SSTR+)Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)

Estimated

~$50 – $2,100

Actual pay is set by the research site.

Novartis PharmaceuticalsNCT06784752

Phase 1

Phase 1 First-in-Human, Dose Escalation and Dose Expansion Study of RYZ401, a Novel Radiopharmaceutical Therapy Labeled With Actinium-225, in Subjects With Neuroendocrine Tumors and Other Solid Tumors Expressing Somatostatin Receptors.

The primary objectives are to determine the recommended Phase 2 dose (RP2D) and optimal treatment regimen, characterize safety and tolerability, and evaluate p…

GEP-NETGastroenteropancreatic Neuroendocrine TumorGastroenteropancreatic Neuroendocrine Tumor Disease+6 more

Estimated

~$150 – $4,200

Actual pay is set by the research site.

RayzeBio, Inc.NCT07165132

Phase 1

Phase I Trial of [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers

Background: Some cancers have high levels of proteins called somatostatin receptors (SSTRs) on the surface of the tumors. These tumors can be in the lung, hea…

Sinonasal Neuroendocrine CarcinomaNasopharyngeal CarcinomaEsthesioneuroblastoma+7 more

Estimated

~$150 – $2,700

Actual pay is set by the research site.

National Cancer Institute (NCI)

Observational

Testing the Impact of Pre-visit Priming as a Mechanism Across Multiple Medication Use Behavioral Targets in Primary Care Practice

We will use EHR data to identify eligible patients at BWH primary care clinics. Patients will be eligible if they have an upcoming primary care provider (PCP) …

DeprescribingStatin Prescribing

Estimated

~$10 – $750

Actual pay is set by the research site.

Brigham and Women's HospitalNCT07281131